Halting GLP-1 Meds Erases Cardiovascular Gains

A BMJ Medicine study of 333,687 veterans shows that stopping GLP-1 therapies (like Ozempic and Wegovy) reverses their cardiovascular benefits quickly: even a 6‑month lapse raises the risk of heart attack and stroke, and longer interruptions erode protection further. Continuous GLP-1 use was linked to fewer major cardiovascular events, while stopping can also lead to weight regain and withdrawal symptoms; tapering off with medical guidance and maintaining a healthy lifestyle is advised, underscoring that GLP-1 benefits are long‑term risk‑reduction rather than a quick fix.